Related references
Note: Only part of the references are listed.Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
Richard P. Gale et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2020)
Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept
Chikako Hara et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
Ali Dirani et al.
CLINICAL OPHTHALMOLOGY (2018)
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
Parmis Parvin et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice
Raphaelle Despreaux et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2016)
PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB Time Course and Drug Effects
Sophie De Massougnes et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
Shiqi Yang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration
Cheryl A. Arcinue et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results
C. Gianniou et al.
EYE (2015)
Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
Irmela Mantel et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
Heidi Fassnacht-Riederle et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2014)
Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration
Andrew A. Chang et al.
OPHTHALMOLOGY (2014)
Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration
Christian Simader et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
David R. Griffin et al.
JOURNAL OF OPHTHALMOLOGY (2014)
Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors
Vincent Y. Ho et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab
Benjamin Bakall et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Nishant Kumar et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
Susanne Binder
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
Michael W. Stewart
CLINICAL OPHTHALMOLOGY (2012)
Predicted biological activity of intravitreal VEGF trap
M. W. Stewart et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2008)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
